Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma
European Journal of Cancer · 2024-08 · 207 · 114146
DOI: 10.1016/j.ejca.2024.114146 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2024-08. Verfasst von Jason J Luke und 19 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA 15232, USA. Electronic address: lukejj@upmc.edu. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung, Melanoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA 15232, USA. Electronic address: lukejj@upmc.edu.
- Melanoma Institute Australia, The University of Sydney, Royal North Shore Hospital, and Mater Hospital, 40 Rocklands Road, North Sydney, NSW 2065, Australia.
- Gustave Roussy and Paris-Saclay University, 114 Rue Edouard Vaillant, Paris, Villejuif, France.
- Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, 40 Rocklands Road, North Sydney, NSW 2065, Australia.
- Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.
- Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA.
Zitieren
APA
Luke, J. J., Long, G. V., Robert, C., Carlino, M. S., Choueiri, T. K., Haas, N. B., O'Brien, M., Paz-Ares, L., Peters, S., Powles, T., Leiby, M. A., Lin, J., Zhao, Y., Krepler, C., Perini, R. F., Catherine Pietanza, M., Samkari, A., Gruber, T., Ibrahim, N., & Eggermont, A. M. M. (2024). Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma. European Journal of Cancer, 207, 114146. https://doi.org/10.1016/j.ejca.2024.114146
Vancouver
Luke JJ, Long GV, Robert C, Carlino MS, Choueiri TK, Haas NB, et al. Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma. European Journal of Cancer. 2024;207:114146. doi:10.1016/j.ejca.2024.114146
BibTeX
@article{Luke2024,
author = {Luke, Jason J and Long, Georgina V and Robert, Caroline and Carlino, Matteo S and Choueiri, Toni K and Haas, Naomi B and O'Brien, Mary and Paz-Ares, Luis and Peters, Solange and Powles, Thomas and Leiby, Melanie A and Lin, Jianxin and Zhao, Yujie and Krepler, Clemens and Perini, Rodolfo F and Catherine Pietanza, M and Samkari, Ayman and Gruber, Todd and Ibrahim, Nageatte and Eggermont, Alexander M M},
title = {Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma},
journal = {European Journal of Cancer},
year = {2024},
volume = {207},
pages = {114146},
doi = {10.1016/j.ejca.2024.114146}
}
EUVIMED